Literature DB >> 9725491

Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias.

V L Lanchote1, E J Cesarino, V J Santos, A V Moraes Júnior, A M Zanardi, S R Santos.   

Abstract

Following a week of racemic mexiletine HCl at 200 mg tid (2x100 mg capsules), stereoselective aliphatic hydroxylation was studied in eight Chagasic women with chronic ventricular arrhythmias (52-67 yrs) with no history of renal or hepatic diseases. Blood samples were collected at dose interval up to 24 h of drug administration. Plasma concentrations of R(-) and S(+) mexiletine (MEX) and its metabolite hydroxymethylmexiletine (HMM) were determined by HPLC after derivatization with chiral reagent. The differences between R(-) and S(+) enantiomers were compared by paired t-test. Results are mean (95% CI). The following differences (p < 0.05) between R(-) and S(+) enantiomers, respectively, were found: MEX AUCss(0-8) 2.34 (1.84-2.85) vs 2.55 (1.97-3.13) microg.ml(-1) x h(-1); MEX CL/f 11.27 (7.77-14.77) vs 10.46 (7.18-13.74)ml.min(-1).Kg(-1); HMM Cmax 38.26 (24.3-52.22) vs 16.73 (10.1-23.29)ng.ml(-1); HMM Tmax 4.71 (2.67-6.76) vs 3.29 (1.24-5.33) h and HMM AUCss(0-8) 253.50 (165.39-341.61) vs 103.70 (69.51-137.90)ng.ml(-1).h(-1). The AUCss(0-8) ratio R(-)/S(+) for MEX was 0.93 (0.87-0.98) while for HMM was 2.50 (2.16-2.85). Distribution of MEX and HMM enantiomers were not significantly different. In this study we demonstrate that kinetic disposition of mexiletine exhibits stereoselectivity in vivo and that aliphatic hydroxylation is favored for R(-) mexiletine in Chagasic women with ventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725491     DOI: 10.1007/BF03189349

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  18 in total

1.  High-performance liquid chromatographic determination of mexiletine enantiomers in plasma using direct and indirect enantioselective separations.

Authors:  V L Lanchote; P S Bonato; S A Dreossi; P V Gonçalves; E J Cesarino; C Bertucci
Journal:  J Chromatogr B Biomed Appl       Date:  1996-10-25

2.  [Pharmacokinetics of mexiletine and its hydroxymethyl metabolite after intramuscular and intravenous administration of mexiletine in healthy subjects].

Authors:  R Levy-Prades; F Philip; T Danays; A Serradimigni; J P Cano
Journal:  Therapie       Date:  1987 Jan-Feb       Impact factor: 2.070

3.  Pharmacokinetics of mexiletine in middle-aged and elderly patients.

Authors:  K Ueno; Y Kawaguchi; K Tanaka
Journal:  Clin Pharm       Date:  1993-10

4.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

5.  Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.

Authors:  P Lledó; S M Abrams; A Johnston; M Patel; R M Pearson; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers.

Authors:  D W Kwok; C R Kerr; K M McErlane
Journal:  Xenobiotica       Date:  1995-11       Impact factor: 1.908

7.  Stereoselective serum protein binding of mexiletine enantiomers in man.

Authors:  K M McErlane; L Igwemezie; C R Kerr
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1987-04

8.  Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.

Authors:  Z Abolfathi; C Fiset; M Gilbert; K Moerike; P M Bélanger; J Turgeon
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

9.  Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms.

Authors:  A H Haedo; P A Chiale; J D Bandieri; J O Lázzari; M V Elizari; M B Rosenbaum
Journal:  J Am Coll Cardiol       Date:  1986-05       Impact factor: 24.094

10.  Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6--a preliminary report.

Authors:  N Vandamme; F Broly; C Libersa; C Courseau; M Lhermitte
Journal:  J Cardiovasc Pharmacol       Date:  1993-01       Impact factor: 3.105

View more
  1 in total

Review 1.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.